表紙
市場調查報告書

抗生素抗藥性、藥物抗性 (AMR) 診斷:各技術、病原菌趨勢、預測 (2020-2024年)

Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2020 to 2024

出版商 Howe Sound Research 商品編碼 928144
出版日期 內容資訊 英文 228 Pages
商品交期: 最快1-2個工作天內
價格
抗生素抗藥性、藥物抗性 (AMR) 診斷:各技術、病原菌趨勢、預測 (2020-2024年) Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2020 to 2024
出版日期: 2020年03月07日內容資訊: 英文 228 Pages
簡介

降低由抗生素抗藥性、藥物抗性 (AMR) 帶來的威脅中,診斷技術發揮了領導作用,開發複數超越遺傳基因定序的新診斷技術。

本報告提供抗生素抗藥性、藥物抗性 (AMR)的診斷的市場調查,市場結構,AMR概要,主要藥物抗性菌(6種) 及診斷技術概要,企業間的各種展開,技術開發趨勢,主要經營者的簡介,市場展望等資料彙整。

第1章 簡介、市場定義

第2章 市場概要

  • 進入經營者、機關所扮演的角色、影響
    • 醫藥品製造商:大、醫藥品
    • 醫藥品製造商:非專利
    • CRO、CMO
    • 體外診斷
    • 醫藥品行銷
    • 生物科技
    • 法規當局
  • 關於抗生素抗藥性、藥物抗性 (AMR)
  • 新的抗生劑、技術的路程的變化
  • AMR的診斷的重要性

第3章 AMR的市場機會

  • 大規模的市場機會
    • 藥物抗性肺炎球菌 (DRSP)
    • 藥物抗性曲狀桿菌 (DRC)
    • 梭狀桿菌 (CD)
    • 抗藥性金黃色葡萄球菌 (MRSA)
    • 藥物抗性淋菌 (DRNG)
    • 藥物抗性沙門菌 (DRNTS)
  • 診斷技術的開發機會
    • 多工 vs. POC/迅速
    • 從複數的病原菌到全部的病原菌:下一代
    • 沒有定序遺傳基因排列診斷
    • 抗性標記等
  • 抗生素抗性:近幾年的發展
    • 食物中毒菌造成的感染疾病的治療困難
    • 灰塵共享抗生素抗性基因
    • Qiagen:啟動AMR資料庫
    • 淋病的抗生素抗性實驗:獲得FDA的BT指定
    • Qiagen、Ares Genetics:AMR生物資訊學授權
    • OpGen:AMR Gene Panel第一次申請510 (k)
    • Curetis子公司AresGenetics: 與Sandoz合作等

第4章 主要生物科技企業和其技術

  • 1928 Diagnostics
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Beckman Coulter, Inc
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (now Danaher)
  • Curetis N.V. / Curetis GmbH
  • Day Zero Diagnostics
  • Enzo Life Sciences, Inc.
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • GenePOC Diagnostics
  • Great Basin Corporation
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Millipore Sigma
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Roche Diagnostics
  • SeLux Diagnostics
  • Sense Biodetection
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc

第5章 全球市場:各國

第6章 全球市場:各病原菌

  • DRSP
  • DRC
  • CD
  • MRSA
  • DRNG
  • DRNTS

第7章 AMR診斷市場:各技術

  • 細菌培養
  • 免疫檢測
  • 聚合酵素鏈鎖反應 (PCR)
  • 遺傳基因定序
  • 質譜分析設備
  • 迅速診斷、POC診斷、其他

第8章 AMR診斷的未來性、願景

目錄

OVERVIEW:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Antimicrobial Resistance - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2. Defining the Opportunity
    • 1.2.1. Revenue Market Size
  • 1.3. Methods and Sources
    • 1.3.1. Authors
    • 1.3.2. Sources
  • 1.4. U.S. Antibiotic Markets - Perspective
    • 1.4.1. U.S. Outpatient Use of Antibiotics
    • 1.4.2. U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1. Market Players - Roles & Impacts
    • 2.1.1. Drug manufacturers - Larger/pharmaceutical
    • 2.1.2. Drug manufacturers - Generic
    • 2.1.3. Contract Research and Manufacturing
    • 2.1.4. In Vitro Diagnostics Industry
    • 2.1.5. Drug Marketing Companies
    • 2.1.6. Biotechnology Companies
    • 2.1.7. Regulatory Bodies
  • 2.2. Understanding Antimicrobial Resistance
    • 2.2.1. What is Antimicrobial Resistance (AMR)
    • 2.2.2. Bacteria and Other Microbes
    • 2.2.3. The History of Antibiotics
    • 2.2.4. The Role of Animal Husbandry
    • 2.2.5. The Implications of Horizontal Transfer
    • 2.2.6. The Threat of AMR
  • 2.3. The Changing Road to New Antibiotics & Technologies
  • 2.4. The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1. The Key Large Market Opportunities in AMR
    • 3.1.1. Streptococcus Pneumoniae (DRSP)
    • 3.1.2. Campylobacter (DRC)
    • 3.1.3. Clostridium Difficile (CD)
    • 3.1.4. Staphylococcus aureus (MRSA)
    • 3.1.5. Neisseria gonorrhoeae (DRNG)
    • 3.1.6. Salmonella (DRNTS)
  • 3.2. Diagnostic Technology Development Opportunities
    • 3.2.1. What's Wrong with Microbiology
    • 3.2.2. The Features Battleground of Infectious Disease Diagnostics
    • 3.2.3. Multiplex vs. POC/Rapid
    • 3.2.4. The Miracle of Genetics
    • 3.2.5. From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 3.2.6. Gene Sequence Diagnostics WITHOUT the Sequencing.
    • 3.2.7. Markers of Resistance.
    • 3.2.8. What Happens to the Microbiology Lab?
  • 3.4. Antibiotic Resistance Recent Developments
    • Importance of These Developments
    • How to Use This Section
    • Infections with foodborne bacteria becoming harder to treat
    • Dust is sharing antibiotic resistance genes
    • Report predicts drug resistance likely to kill 400,000
    • New method to test for infection resistance.
    • Qiagen launches AMR database
    • Antibiotic resistance test for gonorrhea gets FDA breakthrough
    • Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics
    • OpGen to File First 510(k) for AMR Gene Panel
    • Curetis' Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR
    • GeneCapture to determine antibiotic sensitivity in an automated rapid portable device
    • Quick identification of multidrug-resistant pathogens
    • OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel
    • Metagenomics Enables Researchers to Uncover Drug Resistance Genes
    • Rapid detection of multi-drug-resistant bacteria
    • Improved Diagnostics Fail to Halt the Rise of Tuberculosis
    • High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
    • New solution for diagnosing antibiotic-resistant bacteria
    • MALDI-TOF - Results in Minutes not Days
    • CRISPR Tool Used to Uncover Infections
    • Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
    • BD, Check-Points Receive CE Mark for Resistant Organism Screening Test
    • LiDia® BSI Detects Pathogens and Antimicrobial Resistance
    • New tool can Track Resistant Malaria
    • Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
    • Longitude Funds for POC Tests
    • New test can identify dangerous bacteria with resistance to last-resort antibiotic
    • bioMérieux receives FDA clearance for expanded pathogen identification capability
    • OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
    • Hospital Plumbing Harbors Antibiotic Resistant Bacteria
    • Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
    • Curetis Gets Singapore Approval for Pneumonia Test
    • PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
    • Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

4. Key Biotechnology Companies and Their Technology

  • 1928 Diagnostics
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Beckman Coulter, Inc
  • Becton, Dickinson and Company
  • Binx Health
  • bioMérieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (now Danaher)
  • Curetis N.V. / Curetis GmbH
  • Day Zero Diagnostics
  • Enzo Life Sciences, Inc.
  • Eurofins Scientific
  • Fusion Genomics
  • GeneFluidics
  • GenePOC Diagnostics
  • Great Basin Corporation
  • Hutman Diagnostics
  • Inflammatix
  • Linear Diagnostics
  • Millipore Sigma
  • Ortho Clinical Diagnostics
  • Perkin Elmer
  • Roche Diagnostics
  • SeLux Diagnostics
  • Sense Biodetection
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific Inc

5. The Global Market

  • 5.1. Global Market by Country

6. Global Market by Pathogens

  • 6.1. Global Market by Pathogens
  • 6.2. DRSP
  • 6.3. DRC
  • 6.4. CD
  • 6.5. MRSA
  • 6.5. DRNG
  • 6.6. DRNTS

7. AMR Diagnostics by Technology

  • 7.1. Global Market by Technology
  • 7.2. Bacterial Culture
  • 7.3. Immunoassay
  • 7.4. Polymerase Chain Reaction
  • 7.5. Genetic Sequencing
  • 7.6. Mass Spectrometer
  • 7.7. Rapid, POC and Other

8. Vision of the Future of AMR Diagnostics

Table of Tables

  • Table 1: USA - Outpatient Use of Antibiotics by Class
  • Table 2: USA - Outpatient Use of Antibiotics Top 5
  • Table 3: Market Players by Type
  • Table 4: Known Human Pathogenic Diseases
  • Table 5: The Key Market Opportunities
  • Table 6: Market Potential DRSP Diagnostic
  • Table 7: Market Potential DRC Diagnostic
  • Table 8: Market Potential CD Diagnostic
  • Table 9: Market Potential CD Diagnostic
  • Table 10: Market Potential DRNG Diagnostic
  • Table 11: Market Potential DRNTS Diagnostic
  • Table 12: Key AMR Diagnostics Issues
  • Table 13: The Global AMR Diagnostic Market by Country
  • Table 14: Global Market by Pathogen
  • Table 15: DRSP Diagnostics by Country
  • Table 16: DRC Diagnostics by Country
  • Table 17: CD Diagnostics by Country
  • Table 18: MRSA Diagnostics by Country
  • Table 19: DRNG Diagnostics by Country
  • Table 20: DRNTS Diagnostics by Country
  • Table 21: Global Market by Technology
  • Table 22: Culture Diagnostics by Country
  • Table 23: Immunoassay Diagnostics by Country
  • Table 24: PCR Diagnostics by Country
  • Table 25: NGS Diagnostics by Country
  • Table 26: MS Diagnostics by Country
  • Table 27: Rapid, POC and Other Diagnostics by Country

Table of Figures

  • Figure 1: Pharmaceutical Spending History by Country
  • Figure 2: AMR and Antibiotic Introduction
  • Figure 3: The Death Toll of AMR
  • Figure 4: AMR Diagnostics - Key Countries
  • Figure 5: Chart of Share Change by Pathogen
  • Figure 6: Pathogen Share by Year
  • Figure 7: Pathogen Segment Growth Rates
  • Figure 8: Chart - DRSP Segment vs Total Market
  • Figure 9: Chart - DRC Segment vs Total Market
  • Figure 10: Chart - CD segment vs Total Market
  • Figure 11: Chart - MRSA Segment vs Total Market
  • Figure 12: Chart - DRNG Segment vs Total Market
  • Figure 13: Chart - DRNTS Segment vs Total Market
  • Figure 14: Chart of Growth by Technology
  • Figure 15: Chart - Technology Change in Planning Period
  • Figure 16: Chart - Technology Share by Year
  • Figure 17: Chart - Bacterial Culture vs Total Market
  • Figure 18: Chart - Immunoassay vs Total Market
  • Figure 19: Chart - PCR vs Total Market
  • Figure 20: Chart - NGS vs Total Market
  • Figure 21: Chart - Mass Spectrometry vs Total Market
  • Figure 22: Chart - Rapid POC vs Total Market